<i>Ebi2</i>^{−<b>/</b>−} mice have stronger pDC-mediαted type I IFN responses to <i>in vivo</i> challenge with TLR agonists or LCMV Cl13.

<p><b>A, B.</b> Type I IFN production in mice challenged i.p. with TLR7 agonist Imiquimod (<b>A</b>) or TLR3 agonist poly(I:C) (<b>B</b>). IFN-α and IFN-β concentrations in peritoneal lavage fluid 4 hr following challenge were determined by ELISA. Bars represent mean values (white denotes WT, shaded denotes KO; n = 5 per group); circles represent individual animals. <b>C</b>. LCMV Cl13 infection in <i>Ebi2</i>^−/− mice. <i>Ebi2</i>^−/− (shaded bars) or WT littermate (white bars) mice were infected with 2×10⁶ PFU LCMV Cl13 i.v. On day 3, serum type I IFN concentrations were determined by ELISA. Bars denote mean values; circles represent individual animals (n = 5 per group). <i>P</i>-values are denoted when considered statistically significant (<i>p</i><0.05). IFN-α concentrations in naïve mice were below assay limit of detection.